Effects of family integrated care on refractory cancer-related pain receiving intrathecal morphine pump therapy: a cohort study

Cheng, Yan; Wang, Lina; Zha, Ziying; Zhao, Xiangqin

doi:10.21037/apm-20-1293

Cited by 4 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-one studies were analyzed for the purpose of this review. Three were randomized controlled studies [6,7,20], nine were openlabel prospective studies [9,[20][21][22][25][26][27][28][29], and nine were retrospective studies [29][30][31][32][33][34][35][36][37].…”

Section: Resultsmentioning

confidence: 99%

“…In a prospective study, 33 patients were enrolled for implanting an intrathecal pump because of “refractory cancer-related pain” [ 29 ]. Authors showed that the implantation of intrathecal morphine pump relieved the pain.…”

Section: Discussionmentioning

confidence: 99%

“…No specific information regarding an “intractable pain condition” was reported. Of interest, some of them appeared opioid naive[ 29 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Refractory Cancer Pain and Intrathecal Therapy: Critical Review of a Systematic Review

Mercadante

2023

Pain Ther

View full text Add to dashboard Cite

This critical review assessed the advantages of invasive procedures that were recently included in systematic reviews, to evaluate whether the definition of refractory pain condition was correctly followed to select patients for invasive interventions and to analyze how data were positively interpreted. A total of 21 studies were selected for the purpose of this review. Three were randomized controlled studies, ten were prospective studies, and eight were retrospective studies. Analysis of these studies showed evident lack of proper assessment before implantation for different reasons. These included an optimistic interpretation regarding the outcomes, poor consideration of complica-tions, and inclusion of patients with short survival. Moreover, the indication of intrathecal therapy as a condition in which a patient has failed to respond to multiple therapies provided by a pain or palliative care physician or at sufficient doses for adequate durations, as suggested by a recent research group, has been disregarded. Regretfully, this can discourage the use of intrathecal therapy in patients who are unresponsive to multiple opioid strategies subtrahend a potent means to be used in a very selective population.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Refractory Cancer Pain and Intrathecal Therapy: Critical Review of a Systematic Review

Mercadante

2023

Pain Ther

View full text Add to dashboard Cite

show abstract

“…Another prospective study of 33 patients receiving morphine ITDD reported significant improvement in mean pain scores, Karnofsky performance scores (KPS), self-rating anxiety and depression scale scores at 1 year follow-up ( P < 0.001) [26]. No serious adverse events were observed in this study [26].…”

Section: Intrathecal Drug Deliverymentioning

confidence: 99%

Neuromodulation techniques for cancer pain management

Magee

Schutzer-Weissmann

Pereira

et al. 2021

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of reviewAdvanced pain management techniques may be indicated in 5-15% of cancer patients. Despite this, a recent review identified that, over the course of 1 year in England, only 458 patients received a procedure intended to provide analgesia and only 30 patients had intrathecal drug delivery (ITDD) devices implanted. This article describes the emerging evidence for ITDD in cancer pain and provides a narrative review of other neuromodulatory techniques (including spinal cord stimulation, peripheral nerve stimulation and acupuncture), approaches that might be employed to address this area of significant unmet clinical need. Recent findingsNumerous studies have been published within the last year reporting positive outcomes associated with ITDD in cancer pain management. Neuromodulation represents an important strategy in the management of persistent pain. Whilst the nonmalignant pain evidence-base is rapidly growing, it remains sparse for cancer pain management. The growing cohort of cancer survivors may significantly benefit from neuromodulatory techniques. SummaryITDD and other neuromodulatory techniques for cancer pain management appear underutilised in the UK and offer the prospect of better treatment for cancer patients with refractory pain or intolerable side-effects from systemic analgesics.

show abstract